Discovery of Clinical Candidate 2-((2S,6S)-2-Phenyl-6-hydroxyadamantan-2-yl)-1-(3'-hydroxyazetidin-1-yl)ethanone [BMS-816336], an Orally Active Novel Selective 11 beta-Hydroxysteroid Dehydrogenase Type 1 Inhibitor.
Ye, X.Y., Chen, S.Y., Wu, S., Yoon, D.S., Wang, H., Hong, Z., O'Connor, S.P., Li, J., Li, J.J., Kennedy, L.J., Walker, S.J., Nayeem, A., Sheriff, S., Camac, D.M., Ramamurthy, V., Morin, P.E., Zebo, R., Taylor, J.R., Morgan, N.N., Ponticiello, R.P., Harrity, T., Apedo, A., Golla, R., Seethala, R., Wang, M., Harper, T.W., Sleczka, B.G., He, B., Kirby, M., Leahy, D.K., Li, J., Hanson, R.L., Guo, Z., Li, Y.X., DiMarco, J.D., Scaringe, R., Maxwell, B., Moulin, F., Barrish, J.C., Gordon, D.A., Robl, J.A.
J. Med. Chem.